Market Newsdesk

Omnicell Completes Acquisition of FDS Amplicare

Expands nationwide footprint of retail pharmacy customers, adding industry-leading financial management, analytics, and population health solutions to EnlivenHealth division offering

Addition of SaaS solutions accelerates EnlivenHealth’s innovation roadmap to help retail pharmacies forecast and reduce DIR fees

Expected to be immediately accretive to non-GAAP EBITDA and non-GAAP earnings per share

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare. The acquisition adds a comprehensive and complementary suite of SaaS financial management, analytics, and population health solutions to Omnicell’s EnlivenHealth™ division.

EnlivenHealth is an industry-leading provider of patient engagement solutions for retail pharmacies and health plans. EnlivenHealth’s mission is to build and orchestrate advanced digital solutions that help its customers to measurably improve patient health outcomes while enabling new clinical services that drive growth and profitability. The addition of FDS Amplicare’s differentiated financial management, analytics, and population health solutions, along with its nationwide network of more than 15,000 independent retail pharmacies, expands EnlivenHealth’s broad industry footprint while complementing the EnlivenHealth offering and mission.

“The digitization of virtually every aspect of healthcare and the COVID-19 pandemic have accelerated fundamental shifts in how, where, and when care is delivered, with retail pharmacies at the forefront of these historic changes,” said Randall Lipps, chairman, president, CEO, and founder of Omnicell. “By combining EnlivenHealth’s strong patient engagement and clinical capabilities with FDS Amplicare’s widely deployed financial and analytics solutions, we are even better positioned to strengthen the health of our retail pharmacy and health plan customers and the patient populations they serve.”

Accelerates DIR Mitigation Solution Roadmap and Leadership

Direct & Indirect Remuneration (DIR) fees continue to challenge the business health of the retail pharmacy industry, especially independent pharmacies. FDS Amplicare’s industry-leading financial management, analytics, and Medicare plan selection solutions are important components that are helping retail pharmacies to manage, forecast, and mitigate their DIR fee exposure. Combined with EnlivenHealth’s proven clinical and data science capabilities, this differentiated, multi-pronged offering is designed to enable retail pharmacies to bend the DIR growth curve.

Under the terms of the purchase agreement, the acquisition price was $177 million, subject to customary adjustments. The FDS Amplicare business that is being acquired recorded approximately $29 million in total revenue (unaudited) for the 12 months ended June 30, 2021. Omnicell used available cash on its balance sheet to finance the transaction, which is expected to be immediately accretive to Omnicell’s non-GAAP EBITDA and non-GAAP Earnings per share.

“With the addition of these new capabilities, EnlivenHealth now offers the industry’s most comprehensive suite of digital technology solutions that are proven to help retail pharmacies and health plans grow and succeed in the new digital-driven era of healthcare,” said Scott Seidelmann, executive vice president and chief commercial officer, Omnicell. “We are thrilled to welcome our new colleagues from FDS Amplicare to the Omnicell/EnlivenHealth family. We look forward to working with them to advance our shared vision of being the most trusted partner for pharmacies and health plans to ensure the lifelong, optimal health of patients.”

Additional details of this acquisition are included in an investor presentation found in the Investor Relations section of our website, www.omnicell.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the expected benefits of the acquisition of the FDS Amplicare business, including on Omnicell’s non-GAAP EBITDA and non-GAAP earnings per share, the impact of the acquisition on Omnicell’s products and services and the capabilities of the products and services of the FDS Amplicare business. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “plan,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seeks,” “predicts,” and “projects” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. There are a significant number of factors that involve substantial known and unknown risks and uncertainties, which could cause actual results to differ materially from statements made in this release, including, among other things: (i) difficulties encountered in integrating the acquired business, including technologies, personnel, and operations; (ii) costs related to the acquisition of FDS Amplicare; (iii) market acceptance of the acquisition of FDS Amplicare and resulting products and services; (iv) Omnicell’s inability to realize value from its significant investments in its business, including product and service innovations; (v) general market, political, economic, and business conditions, including the ongoing COVID-19 pandemic, and other industry or economic conditions outside of Omnicell’s control; and (vi) other risks and uncertainties described in Part I, Item 1A, “Risk Factors” in Omnicell’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated in Omnicell’s subsequently filed Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission (“SEC”), and in Omnicell’s other filings with the SEC. Forward-looking statements should be considered in light of these risks and uncertainties. Investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, new information, future events, or otherwise, except as required by law.

Advisors

Evercore served as financial advisor and provided a fairness opinion to Omnicell and Sidley Austin LLP served as legal counsel to Omnicell. Baird served as financial advisor to FDS Amplicare, and Willkie Farr & Gallagher served as legal counsel to FDS Amplicare.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

OMNICELL, the Omnicell logo and EnlivenHealth are registered trademarks or trademarks of Omnicell, Inc. or one of its subsidiaries.

OMCL-E

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909006079/en/

Kathleen Nemeth

Omnicell, Inc.

(650)-435-3318

[email protected]

Betsy Martinelli

Omnicell, Inc.

(724) 741-8341

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Health Technology Managed Care Software Pharmaceutical

MEDIA:

Logo

Western Asset Mortgage Capital Corporation Announces Proposed Public Offering of Convertible Senior Notes Due 2024

PASADENA, Calif.–(BUSINESS WIRE)–
Western Asset Mortgage Capital Corporation (NYSE: WMC) (the “Company”) today announced that it intends to offer, subject to market and other conditions, Convertible Senior Notes due 2024 (the “Notes”). The Company intends to grant the underwriter a 30-day option to purchase additional Notes to cover over-allotments, if any.

The Notes will pay interest semiannually and are expected to mature on September 15, 2024, unless earlier converted, redeemed or repurchased. The Company will have the right to redeem the Notes on or after June 15, 2024. Prior to June 15, 2024, the Notes will be convertible only upon certain circumstances and during certain periods, and thereafter will be convertible at any time prior to the close of business on the second business day immediately preceding the maturity date of the Notes. The Notes will be convertible into cash, shares of the Company’s common stock or a combination thereof, at the Company’s sole election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing the offering.

The Company intends to use the net proceeds from this offering, together with up to $25 million of cash on hand, to repurchase additional amounts of its outstanding 6.75% Convertible Senior Notes due October 1, 2022 and the remainder, if any, of the net proceeds for general corporate purposes.

JMP Securities is the sole underwriter for the offering.

The offering is being made pursuant to an effective shelf registration statement, including a prospectus and related prospectus supplement, filed by the Company with the Securities and Exchange Commission (“SEC”). These documents may be obtained for free by visiting the SEC’s website at http://www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, by contacting JMP Securities, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus Department, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT WESTERN ASSET MORTGAGE CAPITAL CORPORATION

Western Asset Mortgage Capital Corporation is a real estate investment trust that invests in, acquires and manages a diverse portfolio of assets consisting of Residential Whole Loans, Commercial Loans, Non-Agency CMBS, Non-Agency RMBS, GSE Risk Transfer Securities and to a lesser extent Agency RMBS, Agency CMBS and ABS. The Company’s investment strategy may change, subject to the Company’s stated investment guidelines, and is based on its manager Western Asset Management Company, LLC’s perspective of which mix of portfolio assets it believes provide the Company with the best risk-reward opportunities at any given time. The Company is externally managed and advised by Western Asset Management Company, LLC, an investment advisor registered with the Securities and Exchange Commission and a wholly-owned subsidiary of Franklin Resources, Inc.

FORWARD-LOOKING STATEMENTS

Certain items in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the proposed offering and the anticipated use of the net proceeds from the offering. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company can give no assurance that its expectations will be attained. Factors that may cause actual results to vary from our forward-looking statements include, but are not limited to, the economic and market impact of the COVID-19 pandemic, many of which are difficult to predict and are generally beyond the Company’s control. In particular, it is difficult to fully assess the impact of COVID-19 at this time due to, among other factors, uncertainty regarding the severity and duration of the outbreak domestically and internationally and the effectiveness of federal, state and local governments’ efforts to contain the spread of COVID-19 and respond to its direct and indirect impact on the U.S. economy and economic activity. Other factors are described in Risk Factors section of the Company’s annual report on Form 10-K for the period ended December 31, 2020 filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909006073/en/

Investor Relations Contact:

Larry Clark

Financial Profiles, Inc.

(310) 622-8223

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on September 9, 2021 4:13 pm

Hoonah Indian Association and Alaska Communications to Provide Gigabit Internet Service in Hoonah and Gustavus

Hoonah Indian Association and Alaska Communications to Provide Gigabit Internet Service in Hoonah and Gustavus

HOONAH, Alaska–(BUSINESS WIRE)–
Nearly 1,250 Alaskans in Hoonah and Gustavus, two isolated communities in Southeast Alaska, will receive fiber optic cable-based high-speed internet for the first time, if the National Telecommunications and Information Administration (NTIA) approves a request for a tribal broadband grant.

Hoonah Indian Association and Alaska Communications, together, would connect the region with a subsea fiber optic cable, with fiber to the home in the communities of Hoonah and Gustavus. Alaska Communications would offer Gigabit service in communities that today cannot stream classes, work remotely or access quality telehealth care.

Hoonah Indian Association and Alaska Communications would also provide a community technology center in Hoonah and Gustavus to facilitate broadband education, awareness, training, access, equipment and provide support for community members. The technology center would offer basic skills training, access to social and medical services, and support community cultural activities.

“Bridging the digital divide will bring significant economic and cultural opportunities to our region. The fiber optic network would finally bring reliable, affordable, and high-speed internet so desperately needed to connect our youth with Elders, offer training opportunities, remote work opportunities and distance learning and healthcare. It will transform our region,” said Robert Starbard, Tribal Administrator, Hoonah Indian Association.

“We thank the Hoonah Indian Association and NTIA for this opportunity to continue connecting and serving our fellow Alaskans. This fiber optic network would positively change lives and spur economic growth in the region. We are proud to be part of this important project,” said Bill Bishop, president and CEO, Alaska Communications.

Once constructed, the Hoonah and Gustavus fiber optic network would connect to the Alaska Communications core fiber network.

Grant applications were submitted to the NTIA Tribal Broadband Connectivity Program Sept. 1. NTIA expects to award grants by the end of 2021. If awarded, the project would be complete in December 2023.

Hoonah Indian Association

Hoonah Indian Association, headquartered in Hoonah Alaska is the federally recognized tribal government of the Xunaa Tlingit.

Alaska Communications

Alaska Communications, an affiliate of ATN International, Inc. (NASDAQ: ATNI), is the leading provider of advanced broadband and managed IT services for businesses and consumers in Alaska. The company operates a highly reliable, advanced statewide data network with the latest technology and the most diverse undersea fiber optic system connecting Alaska to the contiguous U.S. For more information, visit www.AlaskaCommunications.com or www.alsk.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909006026/en/

Robert Starbard, Hoonah Indian Association

907-723-7791

Heather Cavanaugh, Alaska Communications

907-564-7722

KEYWORDS: Alaska United States North America

INDUSTRY KEYWORDS: Native American Consumer Technology Telecommunications Mobile/Wireless Networks Internet

MEDIA:

Posted on September 9, 2021 4:13 pm

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.–(BUSINESS WIRE)–
Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 44,200 shares of the Company’s common stock at an exercise price per share of $34.31, which was the closing price on September 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: Etrumadenant (AB928), the first dual A_2a/A_2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, and non-small cell lung. Quemliclustat (AB680), the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development in combination with zimberelimab and gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study evaluating zimberelimab monotherapy, domvanalimab plus zimberelimab and domvanalimab plus etrumadenant plus zimberelimab for first-line treatment of PD-L1 ≥ 50% metastatic non-small cell lung cancer (NSCLC). In addition, domvanalimab has advanced into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab and is expected to advance into a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage 3 NSCLC setting later this year. AB308, an anti-TIGIT antibody that is FcR-enabled, is in clinical development, with a potential focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909006014/en/

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

ICL to Present at CL King’s 19^th Annual Best Ideas Conference

TEL AVIV, Israel–(BUSINESS WIRE)–ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced Kobi Altman, CFO of ICL, will be presenting at CL King’s 19^th Annual Best Ideas Conference at 8:00 a.m. ET on Tuesday, September 14, 2021.

A webcast of the event will be available at investors.icl-group.com/reports-news-and-events/default.aspx#events. A replay will be available at the same site for a limited time, following the live event.

About ICL

ICL Group is a leading global specialty minerals company, which also benefits from commodity upside. The company creates impactful solutions for humanity’s sustainability challenges in global food, agriculture, and industrial markets. ICL leverages its unique bromine, potash and phosphate resources, its passionate team of talented employees, and its strong focus on R&D and technological innovation to drive growth across its end markets. ICL shares are dually listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL). The company employs more than 12,000 people worldwide, and its 2020 revenues totaled approximately $5.0 billion.

For more information, visit ICL’s website at www.icl-group.com.

To access ICL’s interactive Corporate Social Responsibility report, please click here.

You can also learn more about ICL on Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005935/en/

Investor Relations Contacts

Peggy Reilly Tharp

VP, Global Investor Relations

+1-314-983-7665

[email protected]

Dudi Musler

Director, Investor Relations

+972-3-684-4448

[email protected]

Press Contact

Adi Bajayo

Scherf Communications

+972-52-4454789

[email protected]

KEYWORDS: Israel Middle East

INDUSTRY KEYWORDS: Agriculture Natural Resources Environment Mining/Minerals

MEDIA:

Logo